16.78  -0.12 (-0.71%)		04-24 10:46
Open: 16.78 High: 16.78 Volume: 756		Pre. Close: 16.9 Low: 16.78 Market Cap: 11(M)

Short term
Mid term
Targets	6-month :	20.63	1-year :	21.6
Resists	First :	17.66	Second :	18.5
Pivot price	17.15
Supports	First :	16.31	Second :	13.57
MAs	MA(5) :	16.63	MA(20) :	17.42
	MA(100) :	18.35	MA(250) :	18.84
MACD	MACD :	-0.5	Signal :	-0.4
%K %D	K(14,3) :	24.3	D(3) :	15.6
RSI	RSI(14): 36
52-week	High :	21.7	Low :	15.67

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GERM ] has closed above bottom band by 33.7%. Bollinger Bands are 70.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	17.06 - 17.14	17.14 - 17.21
Low:	16.69 - 16.79	16.79 - 16.88
Close:	16.74 - 16.9	16.9 - 17.04

The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund invests at least 80% of its total assets in the component securities of the index. The fund is non-diversified.

Tue, 23 Apr 2024
Amplify Treatments, Testing and Advancements ETF (NYSEARCA:GERM) Trading 1.8% Higher - Defense World

Mon, 29 Jan 2024
Amplify ETFs Completes Acquisition to Reach $9.1 Billion AUM Across 31 ETFs - Yahoo Finance

Thu, 04 Jan 2024
Form DEFA14A ETF Managers Trust - StreetInsider.com

Thu, 22 Jun 2023
Biotech ETFs in Focus on Covid Vaccines' Fall Rollout - Yahoo Finance

Mon, 20 Dec 2021
Biotech ETFs That Outperformed Last Week - Yahoo Finance

Tue, 12 Oct 2021
Why ETFs may be the best way to bet on the future of biotech - The Globe and Mail

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: AMEX
Sector: Financial Services
Industry: Asset Management
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.